References
Fuchs, C., Wauschkuhn, S., Scheer, C., Vollmer, M., Meissner, K., Kuhn, S. O.,… & Rehberg, S. (2017). Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. BJA: British Journal of Anaesthesia, 119(4), 616-625. Web.
Goldstein, E., MacFadden, D. R., Karaca, Z., Steiner, C. A., Viboud, C., & Lipsitch, M. (2019). Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states. International Journal of Antimicrobial Agents, 54(1), 23-34. Web.
Goodwin, A. J., Nadig, N. R., McElligott, J. T., Simpson, K. N., & Ford, D. W. (2016). Where you live matters: The impact of place of residence on severe sepsis incidence and mortality. Chest, 150(4), 829-836. Web.
Hatfield, K. M., Dantes, R. B., Baggs, J., Sapiano, M. R., Fiore, A. E., Jernigan, J. A., & Epstein, L. (2018). Assessing variability in hospital-level mortality among US medicare beneficiaries with hospitalizations for severe sepsis and septic shock. Critical Care Medicine, 46(11), 1753. Web.
Luhr, R., Cao, Y., Soederquist, B., & Cajander, S. (2019). Trends in sepsis mortality over time in randomized sepsis trials: A systematic literature review and meta-analysis of mortality in the control arm, 2002–2016. Critical Care, 23(1), 1-9. Web.